Trial Profile

A phase 1/2 study of FYB207 for COVID-2019 Infections

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FYB 207 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Formycon

Most Recent Events

11 Aug 2021 According to a Formycon media release, Phase I/IIa clinical trial expected to start first half of 2022.
12 Jul 2021 According to a Formycon media release, the company has received the final notification for a grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy in the amount of Euro 12.7 million to support this study.
12 Jul 2021 According to a Formycon media release, the company expects to start this study in the fourth quarter of 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com